JP2012082215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012082215A5 JP2012082215A5 JP2011273983A JP2011273983A JP2012082215A5 JP 2012082215 A5 JP2012082215 A5 JP 2012082215A5 JP 2011273983 A JP2011273983 A JP 2011273983A JP 2011273983 A JP2011273983 A JP 2011273983A JP 2012082215 A5 JP2012082215 A5 JP 2012082215A5
- Authority
- JP
- Japan
- Prior art keywords
- effective amount
- therapeutically effective
- day
- use according
- prednisone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004103 abiraterone acetate Drugs 0.000 claims 22
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims 22
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 22
- 229960004618 prednisone Drugs 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 21
- 239000002246 antineoplastic agent Substances 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 206010060862 Prostate cancer Diseases 0.000 claims 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 8
- 229940041181 antineoplastic drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 239000000051 antiandrogen Substances 0.000 claims 6
- 230000002280 anti-androgenic effect Effects 0.000 claims 5
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 3
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 claims 3
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 3
- 108010069236 Goserelin Proteins 0.000 claims 3
- 108010000817 Leuprolide Proteins 0.000 claims 3
- 108010050144 Triptorelin Pamoate Proteins 0.000 claims 3
- 229960000997 bicalutamide Drugs 0.000 claims 3
- 229960005408 deslorelin Drugs 0.000 claims 3
- 108700025485 deslorelin Proteins 0.000 claims 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims 3
- 229960002074 flutamide Drugs 0.000 claims 3
- 229960002913 goserelin Drugs 0.000 claims 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 3
- 229960004338 leuprorelin Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims 3
- 229960002653 nilutamide Drugs 0.000 claims 3
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims 3
- 229960004824 triptorelin Drugs 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92150606P | 2006-08-25 | 2006-08-25 | |
| US60/921,506 | 2006-08-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009525647A Division JP2010501575A (ja) | 2006-08-25 | 2007-08-23 | 癌を治療するための方法及び組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014254864A Division JP2015110577A (ja) | 2006-08-25 | 2014-12-17 | 癌を治療するための方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012082215A JP2012082215A (ja) | 2012-04-26 |
| JP2012082215A5 true JP2012082215A5 (cg-RX-API-DMAC7.html) | 2013-02-14 |
| JP6053279B2 JP6053279B2 (ja) | 2016-12-27 |
Family
ID=38916904
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009525647A Pending JP2010501575A (ja) | 2006-08-25 | 2007-08-23 | 癌を治療するための方法及び組成物 |
| JP2011273983A Active JP6053279B2 (ja) | 2006-08-25 | 2011-12-15 | 癌を治療するための方法及び組成物 |
| JP2014254864A Pending JP2015110577A (ja) | 2006-08-25 | 2014-12-17 | 癌を治療するための方法及び組成物 |
| JP2016224393A Pending JP2017052791A (ja) | 2006-08-25 | 2016-11-17 | 癌を治療するための方法及び組成物 |
| JP2017243588A Active JP6445123B2 (ja) | 2006-08-25 | 2017-12-20 | 癌を治療するための方法及び組成物 |
| JP2018222531A Withdrawn JP2019059750A (ja) | 2006-08-25 | 2018-11-28 | 癌を治療するための方法及び組成物 |
| JP2020057344A Active JP6740497B2 (ja) | 2006-08-25 | 2020-03-27 | 癌を治療するための方法及び組成物 |
| JP2020193403A Withdrawn JP2021038252A (ja) | 2006-08-25 | 2020-11-20 | 癌を治療するための方法及び組成物 |
| JP2022161610A Withdrawn JP2022185091A (ja) | 2006-08-25 | 2022-10-06 | 癌を治療するための方法及び組成物 |
| JP2024140948A Pending JP2024164147A (ja) | 2006-08-25 | 2024-08-22 | 癌を治療するための方法及び組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009525647A Pending JP2010501575A (ja) | 2006-08-25 | 2007-08-23 | 癌を治療するための方法及び組成物 |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014254864A Pending JP2015110577A (ja) | 2006-08-25 | 2014-12-17 | 癌を治療するための方法及び組成物 |
| JP2016224393A Pending JP2017052791A (ja) | 2006-08-25 | 2016-11-17 | 癌を治療するための方法及び組成物 |
| JP2017243588A Active JP6445123B2 (ja) | 2006-08-25 | 2017-12-20 | 癌を治療するための方法及び組成物 |
| JP2018222531A Withdrawn JP2019059750A (ja) | 2006-08-25 | 2018-11-28 | 癌を治療するための方法及び組成物 |
| JP2020057344A Active JP6740497B2 (ja) | 2006-08-25 | 2020-03-27 | 癌を治療するための方法及び組成物 |
| JP2020193403A Withdrawn JP2021038252A (ja) | 2006-08-25 | 2020-11-20 | 癌を治療するための方法及び組成物 |
| JP2022161610A Withdrawn JP2022185091A (ja) | 2006-08-25 | 2022-10-06 | 癌を治療するための方法及び組成物 |
| JP2024140948A Pending JP2024164147A (ja) | 2006-08-25 | 2024-08-22 | 癌を治療するための方法及び組成物 |
Country Status (20)
| Country | Link |
|---|---|
| EP (3) | EP2478907B1 (cg-RX-API-DMAC7.html) |
| JP (10) | JP2010501575A (cg-RX-API-DMAC7.html) |
| KR (4) | KR20090059126A (cg-RX-API-DMAC7.html) |
| CN (2) | CN101528308A (cg-RX-API-DMAC7.html) |
| AU (6) | AU2007287098C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2661422C (cg-RX-API-DMAC7.html) |
| CY (2) | CY1115477T1 (cg-RX-API-DMAC7.html) |
| DK (2) | DK2061561T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2428634T3 (cg-RX-API-DMAC7.html) |
| HR (2) | HRP20130961T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE054495T2 (cg-RX-API-DMAC7.html) |
| IL (3) | IL197211A0 (cg-RX-API-DMAC7.html) |
| LT (1) | LT2478907T (cg-RX-API-DMAC7.html) |
| NO (2) | NO20091190L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ597830A (cg-RX-API-DMAC7.html) |
| PL (2) | PL2478907T3 (cg-RX-API-DMAC7.html) |
| PT (2) | PT2061561E (cg-RX-API-DMAC7.html) |
| RS (2) | RS52956B (cg-RX-API-DMAC7.html) |
| SI (2) | SI2061561T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008024484A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090059126A (ko) * | 2006-08-25 | 2009-06-10 | 코우가 바이오테크놀로지, 인크. | 암을 치료하기 위한 방법 및 조성물 |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| US20090124587A1 (en) * | 2007-07-12 | 2009-05-14 | Auerbach Alan H | METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS |
| RU2481107C2 (ru) * | 2007-10-29 | 2013-05-10 | Такеда Фармасьютикал Компани Лимитед | Средство для профилактики или лечения рака |
| CN102558274B (zh) * | 2010-12-08 | 2014-10-15 | 深圳万乐药业有限公司 | 一种适合工业化生产醋酸阿比特龙的合成方法 |
| CN102558275A (zh) * | 2010-12-20 | 2012-07-11 | 天津药物研究院 | α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物 |
| BR112013017722A2 (pt) | 2011-01-11 | 2016-07-12 | Glaxosmithkline Llc | combinação |
| WO2012135759A1 (en) | 2011-04-01 | 2012-10-04 | Genentech, Inc. | Combinations of akt inhibitor compounds and abiraterone, and methods of use |
| US20120295932A1 (en) * | 2011-05-17 | 2012-11-22 | Western Connecticut Health Network, Inc. | Method for the treatment of cancer |
| CN103070828B (zh) * | 2011-10-26 | 2016-01-27 | 山东新时代药业有限公司 | 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法 |
| CN102336801B (zh) * | 2011-10-31 | 2013-05-15 | 南京卡文迪许生物工程技术有限公司 | 醋酸阿比特龙多晶型物和药用组合物 |
| GB201207886D0 (en) * | 2012-05-04 | 2012-06-20 | Jagotec Ag | Improvements in or relating to organic compounds |
| BR112014030099A2 (pt) * | 2012-06-06 | 2017-06-27 | Novartis Ag | combinação de um inibidor 17-alfa-hidroxilase(c17,20-liase) e um inibidor pi-3 k específico para tratamento de uma doença de tumor |
| EA030128B1 (ru) | 2012-09-26 | 2018-06-29 | Арагон Фармасьютикалз, Инк. | Способ лечения неметастатического кастрационно-резистентного рака простаты |
| CN103800296A (zh) * | 2012-11-13 | 2014-05-21 | 重庆医药工业研究院有限责任公司 | 一种稳定的阿比特龙口服固体药物组合物及其制备方法 |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| KR20180021932A (ko) * | 2013-03-15 | 2018-03-05 | 아이슈티카 인코포레이티드 | 아비라테론 아세테이트 제제 |
| US20150246060A1 (en) | 2013-03-15 | 2015-09-03 | Iceutica Inc. | Abiraterone Acetate Formulation and Methods of Use |
| US20160082019A1 (en) * | 2013-04-04 | 2016-03-24 | Exelixis, Inc. | Drug Combinations to Treat Cancer |
| US20150157646A1 (en) | 2013-09-27 | 2015-06-11 | Iceutica Inc. | Abiraterone Steroid Formulation |
| BR112016006976A2 (pt) * | 2013-10-01 | 2017-08-01 | Novartis Ag | combinação |
| KR101797415B1 (ko) * | 2013-10-01 | 2017-11-13 | 노파르티스 아게 | 암의 치료를 위한 아푸레세르팁과 조합된 엔잘루타미드 |
| CN104546745A (zh) * | 2013-10-14 | 2015-04-29 | 深圳海王药业有限公司 | 醋酸阿比特龙的片剂组合物及其制备工艺 |
| US10722527B2 (en) | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
| CN109640991A (zh) | 2016-07-29 | 2019-04-16 | 詹森药业有限公司 | 治疗前列腺癌的方法 |
| JOP20190244A1 (ar) * | 2017-04-13 | 2019-10-13 | Janssen Pharmaceutica Nv | تركيبة علاجية لسرطان البروستاتا |
| KR20240096623A (ko) | 2017-10-16 | 2024-06-26 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
| CN109718198A (zh) * | 2017-10-30 | 2019-05-07 | 浙江京新药业股份有限公司 | 一种治疗前列腺癌的注射剂及其制备方法 |
| CA3131034A1 (en) | 2019-03-06 | 2020-09-10 | Matthew J. Sharp | Abiraterone prodrugs |
| WO2021031991A1 (zh) * | 2019-08-16 | 2021-02-25 | 中国科学院分子细胞科学卓越创新中心 | 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法 |
| US20230158047A1 (en) * | 2020-04-16 | 2023-05-25 | Tavanta Therapeutics Hungary Incorporated | Methods and compositions for treating prostate cancer |
| CN114560903B (zh) * | 2022-03-09 | 2023-08-01 | 绍兴市上虞区武汉理工大学高等研究院 | 一种阿比特龙衍生物的制备方法及其细胞毒性评价 |
| LU506495B1 (en) | 2024-03-01 | 2025-09-01 | Alfasan Nederland B V | 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| DE69327096T2 (de) | 1992-03-31 | 2000-06-21 | Btg International Ltd., London | 17-substituierte steroide, verwendbar bei behandlung von krebs |
| EP1276482B1 (en) * | 2000-03-02 | 2008-01-16 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Combination chemotherapy |
| EP1351678A2 (en) * | 2001-01-02 | 2003-10-15 | Elizabeth Shanahan-Prendergast | Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens |
| CA2503549C (en) * | 2002-10-23 | 2012-07-10 | Pantarhei Bioscience B.V. | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy |
| WO2004062620A2 (en) * | 2003-01-13 | 2004-07-29 | Cedars-Sinai Medical Center | Paricalcitol as a chemotherapeutic agent |
| US20060030608A1 (en) * | 2004-08-04 | 2006-02-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti aromatase compounds pharmaceutical compositions and uses thereof |
| GB0418900D0 (en) * | 2004-08-24 | 2004-09-29 | Btg Int Ltd | Novel salt forms |
| KR20090059126A (ko) | 2006-08-25 | 2009-06-10 | 코우가 바이오테크놀로지, 인크. | 암을 치료하기 위한 방법 및 조성물 |
-
2007
- 2007-08-23 KR KR1020097005974A patent/KR20090059126A/ko not_active Ceased
- 2007-08-23 EP EP12160586.9A patent/EP2478907B1/en not_active Revoked
- 2007-08-23 EP EP07837326.3A patent/EP2061561B1/en not_active Revoked
- 2007-08-23 AU AU2007287098A patent/AU2007287098C1/en active Active
- 2007-08-23 PL PL12160586T patent/PL2478907T3/pl unknown
- 2007-08-23 KR KR1020207031218A patent/KR20200125776A/ko not_active Ceased
- 2007-08-23 CA CA2661422A patent/CA2661422C/en active Active
- 2007-08-23 ES ES07837326T patent/ES2428634T3/es active Active
- 2007-08-23 HR HRP20130961TT patent/HRP20130961T1/hr unknown
- 2007-08-23 JP JP2009525647A patent/JP2010501575A/ja active Pending
- 2007-08-23 KR KR1020157025243A patent/KR20150108946A/ko not_active Ceased
- 2007-08-23 HU HUE12160586A patent/HUE054495T2/hu unknown
- 2007-08-23 PT PT78373263T patent/PT2061561E/pt unknown
- 2007-08-23 LT LTEP12160586.9T patent/LT2478907T/lt unknown
- 2007-08-23 PL PL07837326T patent/PL2061561T3/pl unknown
- 2007-08-23 DK DK07837326.3T patent/DK2061561T3/da active
- 2007-08-23 KR KR1020177037293A patent/KR20180003636A/ko not_active Ceased
- 2007-08-23 ES ES12160586T patent/ES2869343T3/es active Active
- 2007-08-23 RS RS20130401A patent/RS52956B/sr unknown
- 2007-08-23 WO PCT/US2007/018769 patent/WO2008024484A1/en not_active Ceased
- 2007-08-23 NZ NZ597830A patent/NZ597830A/xx not_active IP Right Cessation
- 2007-08-23 CN CNA2007800385835A patent/CN101528308A/zh active Pending
- 2007-08-23 CN CN201410261671.3A patent/CN104306977A/zh active Pending
- 2007-08-23 SI SI200731334T patent/SI2061561T1/sl unknown
- 2007-08-23 DK DK12160586.9T patent/DK2478907T3/da active
- 2007-08-23 RS RS20210531A patent/RS62034B1/sr unknown
- 2007-08-23 PT PT121605869T patent/PT2478907T/pt unknown
- 2007-08-23 SI SI200732177T patent/SI2478907T1/sl unknown
- 2007-08-23 EP EP20190748.2A patent/EP3804730A1/en not_active Withdrawn
-
2009
- 2009-02-24 IL IL197211A patent/IL197211A0/en unknown
- 2009-03-20 NO NO20091190A patent/NO20091190L/no not_active Application Discontinuation
-
2011
- 2011-12-15 JP JP2011273983A patent/JP6053279B2/ja active Active
-
2013
- 2013-08-01 IL IL227746A patent/IL227746A0/en unknown
- 2013-08-20 CY CY20131100709T patent/CY1115477T1/el unknown
-
2014
- 2014-12-17 JP JP2014254864A patent/JP2015110577A/ja active Pending
-
2015
- 2015-08-31 AU AU2015221447A patent/AU2015221447B9/en not_active Ceased
-
2016
- 2016-11-17 JP JP2016224393A patent/JP2017052791A/ja active Pending
-
2017
- 2017-03-15 AU AU2017201764A patent/AU2017201764A1/en not_active Abandoned
- 2017-12-20 JP JP2017243588A patent/JP6445123B2/ja active Active
-
2018
- 2018-02-22 IL IL257681A patent/IL257681A/en unknown
- 2018-11-28 JP JP2018222531A patent/JP2019059750A/ja not_active Withdrawn
- 2018-11-29 AU AU2018271331A patent/AU2018271331A1/en not_active Abandoned
-
2020
- 2020-03-27 JP JP2020057344A patent/JP6740497B2/ja active Active
- 2020-07-01 NO NO20200775A patent/NO20200775A1/no not_active Application Discontinuation
- 2020-11-20 JP JP2020193403A patent/JP2021038252A/ja not_active Withdrawn
-
2021
- 2021-03-16 AU AU2021201649A patent/AU2021201649A1/en not_active Ceased
- 2021-04-27 HR HRP20210670TT patent/HRP20210670T1/hr unknown
- 2021-06-10 CY CY20211100513T patent/CY1124221T1/el unknown
-
2022
- 2022-07-18 AU AU2022206696A patent/AU2022206696A1/en not_active Abandoned
- 2022-10-06 JP JP2022161610A patent/JP2022185091A/ja not_active Withdrawn
-
2024
- 2024-08-22 JP JP2024140948A patent/JP2024164147A/ja active Pending